Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Physicians who Treat Hypertension (US)

Council Members in this Study Group: 792

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Harold Bays, President and Medical Director, L-MARC Research CenterHarold Bays

President and Medical Director
L-MARC Research Center
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Harold Bays, MD, FACP, FACE, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all...

Mark Feinberg

Assistant Professor
HARVARD MEDICAL SCHOOL
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Mark Feinberg, MD, is an Associate Physician and Principal Investigator in the Cardiovascular Division at Brigham and Women's Hospital and an Assistant Professor of Medicine at Harvard Medical School, Massachusetts. He has expertise in the management...

Hossein Ardehali, Assistant Professor, Northwestern University, Feinberg School of MedicineHossein Ardehali

Assistant Professor
Northwestern University, Feinberg School of Medicine
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Hossein Ardehali, MD, PhD, is Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research...

Daniel Fisher

Cardiologist
NEW YORK UNIVERSITY (INC)
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology....

Charles O'Shaughnessy

Director of Interventional Cardiology
NORTH OHIO HEART CENTER, INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Charles O'Shaughnessy, MD, is the Director of Interventional Cardiology at North Ohio Heart Center, Ohio. Dr. O'Shaughnessy's clinical interests are in interventional cardiology including balloon angioplasty, laser directional atherectomy, stent placement,...

View all Leading Experts in this Study Group

GLG NewsSM Analyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Metanalyses, Metapsychoses

September 30, 2009

Controls to blood sugar 'cuts stroke risk' | www.barchester.com

There have been many epidemiologic studies showing a very tight correlation between baseline A1c and cardiovascular mortalityDespite this, five major randomized prospective studies have failed to show any macrovascular benefit for tighter glucose controlThe logical conclusion is that glucose is, therefore, a marker for increased mortality but not a modifiable risk factor thereofThis is why FDA has mandated cardiovascular safety for new antidiabetic agentsData dredging persists, however

If it seems too good to be true...it probably is.

December 9, 2008

Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com

This article implies that physician's have no justifiable reason for prescribing brand-name drugs. Unfortunately, it's not that simple.

“You've got to be very careful if you don't know where you are going, because you might not get there.” Yogi Berra

December 8, 2008

Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows | pharmalive.com

There is a question of bias in this study. It is not prospective, not randomized and not blinded and thus no valid conclusions can be made. The study should be ignored. It will have no impact on sales.

Crestor's results in the Jupiter Study likely to change medical-economic perspectives in statin choices.

November 13, 2008

CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com

1:Crestor is the most potent statin in the market,yet is 3d in sales behind Zocor and Lipitor.2:The efficacy supriority together with its capacity to lower CRP levels led to the highest rate of ASCVD prevention in the shortest period of time evr documented in statin trials.3:The trial in near 18,000 patients with otherwise lower risk of ASCVD offered $0% reduction y many ascvd endpoints.4:There were no statistical differences in side effect compared to placebo.5:The dosage was 20 mg /day (an intermediate dose below the approved max dose of 40 mg/day

Mutiple causes for no publications of many reports on FDA approved drugs.Some problems and solutions.

September 29, 2008

Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com

This article is not news for clinical researchers like myself that have performed hundreds of clinical trials in collaboration with the Pharmaceutical Industry. Some of the most common reasons for that are: A)Negative studies are difficult to get published.B)Negative results for the dug of the sponsor company are of potentially damaging financial  for the sponsor.C)There is no FDA regulation that prohibits a sponsor to deny access to data and freedom of publication to Investigators of the trial not employed by them. Some of the possible solutions for these problems are:A)Complete freedom of access and publication of data by investigators.B)Sponsors of studies be obligated to submit result regardless of outcome,to FDA.C)Studies shall be easily searchable in a Google style manner at  FDA files,by naming a company ,a drug ,a condition,etc,etc.

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Partner
  • Physician - Division Head
  • President

GLG Live Meetings with this Study Group's Leading Experts (?)

August 21, 2008 | Palo Alto

GLG Seminar: (Palo Alto) Heart Failure

May 22, 2008 | Boston

GLG Seminar: Diabetes and Obesity

March 28, 2008 | Boston

GLGi: Lipid Management

Teleconference: Cholesterol War – Merck’s Zetia vs. Abbott’s Niaspan (10:15 AM EST / 15:15 GMT)

11/17/2009

Listen to Archive